Towards the introduction of the 'Immunoscore'in the classification of malignant tumours
…, L Laghi, F Grizzi, M Asslaber, C D'Arrigo… - The Journal of …, 2014 - Wiley Online Library
The American Joint Committee on Cancer/Union Internationale Contre le Cancer ( AJCC /
UICC ) TNM staging system provides the most reliable guidelines for the routine …
UICC ) TNM staging system provides the most reliable guidelines for the routine …
[HTML][HTML] Cancer classification using the Immunoscore: a worldwide task force
…, R Palmqvist, ID Nagtegaal, Y Wang, C d'Arrigo… - Journal of translational …, 2012 - Springer
Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation
of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor …
of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor …
[HTML][HTML] The genetic evolution of melanoma from precursor lesions
…, B Ruben, W Rickaby, C D'Arrigo… - … England Journal of …, 2015 - Mass Medical Soc
Background The pathogenic mutations in melanoma have been largely catalogued;
however, the order of their occurrence is not known. Methods We sequenced 293 cancer-relevant …
however, the order of their occurrence is not known. Methods We sequenced 293 cancer-relevant …
Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130
…, R Deurloo, KP Siziopikou, C D'arrigo… - JNCI: Journal of the …, 2022 - academic.oup.com
Triple-negative breast cancer (TNBC) accounts for approximately 12% to 17% of all breast
cancers and has an aggressive clinical behavior. Increased tumor-infiltrating lymphocyte …
cancers and has an aggressive clinical behavior. Increased tumor-infiltrating lymphocyte …
Paget disease of the nipple: a multifocal manifestation of higher‐risk disease
…, H Hamed, IS Fentiman, C D'Arrigo… - Cancer, 2002 - Wiley Online Library
BACKGROUND The treatment of Paget disease by mastectomy has been challenged
recently in favor of breast‐conserving techniques. A large series of patients treated with …
recently in favor of breast‐conserving techniques. A large series of patients treated with …
[PDF][PDF] CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness
…, PH Warne, M Wagner, R Poulsom, C D'Arrigo… - Cancer cell, 2005 - cell.com
CUTL1, also known as CDP, Cut, or Cux-1, is a homeodomain transcriptional regulator
known to be involved in development and cell cycle progression. Here we report that CUTL1 …
known to be involved in development and cell cycle progression. Here we report that CUTL1 …
Benign central neurocytoma: a double misnomer?
K Ashkan, ATH Casey, C D'Arrigo… - … Journal of the …, 2000 - Wiley Online Library
BACKGROUND “Central neurocytoma” is classically considered as an intraventricular
benign tumor, largely based on data from small retrospective series. The authors present …
benign tumor, largely based on data from small retrospective series. The authors present …
Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine. Part 3: technical validation of immunohistochemistry (IHC) assays in …
EE Torlakovic, CC Cheung, C D'Arrigo… - Applied …, 2017 - journals.lww.com
Validation of immunohistochemistry (IHC) assays is a subject that is of great importance to
clinical practice as well as basic research and clinical trials. When applied to clinical practice …
clinical practice as well as basic research and clinical trials. When applied to clinical practice …
A fully automatic approach for multimodal PET and MR image segmentation in gamma knife treatment planning
…, C Militello, G Russo, MG Sabini, C D'Arrigo… - Computer Methods and …, 2017 - Elsevier
Background and objectives: Nowadays, clinical practice in Gamma Knife treatments is
generally based on MRI anatomical information alone. However, the joint use of MRI and PET …
generally based on MRI anatomical information alone. However, the joint use of MRI and PET …
Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine–Part 2: Immunohistochemistry test performance characteristics
EE Torlakovic, CC Cheung, C D'Arrigo… - Applied …, 2017 - journals.lww.com
All laboratory tests have test performance characteristics (TPCs), whether or not they are
explicitly known to the laboratorian or the pathologist. TPCs are thus also an integral …
explicitly known to the laboratorian or the pathologist. TPCs are thus also an integral …